Biote Corp. (BTMD)

From the record

Biote Corp.'s filings since 2020 show 10 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2022-07-19); a warning not to rely on past financial statements (8-K item 4.02, 2 times, the latest 2023-03-24); an auditor change (8-K item 4.01, the latest 2022-06-02); a late-report notice (Form NT 10-K or NT 10-Q, 5 times, the latest 2022-05-16) (its current reports).

From the record

Biote Corp.'s 5 filed years say what it did: revenue went from $139 million in fiscal 2021 to $192 million in fiscal 2025, up 8.4% a year; it rose in 3 of 4 years; the deepest fall was 3% from fiscal 2024 to fiscal 2025; net income was positive in 4 of 5 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Biote Corp.'s diluted share count grew about 65.7% a year, and dividends and buybacks returned about 22% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 2 purchases of their own stock on the open market in the year to 2026-09-30, buying about $202 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Biote Corp.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 154 cents per dollar of assets, and net share issuance: its share count grew 7.0% over the year (the filed statements).

From the record

Biote Corp.'s standing among 18 graded names in its industry family: revenue of $192 million in fiscal 2025 ranks in the top 25% by size; a net margin of 14.1% ranks in the top 3%; revenue growth of 5.2% a year over the last 3 filed years ranks in the top 47% (its annual reports).

From the record

Biote Corp.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Peterson, Robert Charles (Interim CEO, as filed), filing under that title since 2026-06-16, 5 months (bottom 5% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 4 years (bottom 23%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Biote Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $24 million against debt of $96 million leaves -66.6% of its assets as net cash, bottom 8% of its family; cash from operations less capital spending is 15.7% of revenue (top 8%) (its annual report).

From the record

Biote Corp.'s growth drivers, from the filed years to fiscal 2025: revenue grew 5.2% a year over the last three filed years against 8.4% over all 5, slowing (top 25% of its family); the newest year grew -2.5% (bottom 31%); capital spending grew 146.9% a year (top 9%) (its annual reports). Biote Corp. reported 7 product lines in fiscal 2025: Pellet Procedures Product Revenue at $137 million (71%), Dietary Supplements at $43 million (22%), Disposable Trocars Product Revenue at $5 million (3%), and 4 more; 5 of 7 grew against the year before (its annual report).

From the record

Biote Corp.'s newest year against its own record: revenue of $192 million in fiscal 2025 came in 10.8% below the $216 million its prior three years' pace pointed to (bottom 31% of its family); net income of $27 million against a prior three-year average of $2 million (top 6%); a net margin of 14.1% against 0.9% before (bottom 42%) (its annual reports).